Summary

Education

Ph.D. Pharmaceutical Sciences, University at Buffalo, 2020

B.S. Biochemistry, Binghamton University, 2015

 

Professional Experience

Assistant Professor, Department of Pharmaceutical Sciences, University of Michigan, 2023-present

CEO and Co-founder, Abceutics Inc., 2020-2024

Research Assistant Professor, Department of Pharmaceutical Sciences, University at Buffalo, 2021-2023

 

Research Statement

The Bordeau laboratory focuses on developing innovative antibody-based therapies. One of the significant advantages of antibodies is their remarkable adaptability to engineering, with >100 distinct antibody formats, including intact antibodies, antibody fragments, and bi- and tri-specific antibodies. We employ pharmacokinetic modeling and simulation to identify key antibody attributes including target binding affinity, clearance rates, valency, and molecular size. Simulation results inform antibody engineering campaigns to develop lead antibody therapies for experimental testing.

Research Interests

    1. Antibody Drug Complexes (ADCx)
    2. Antibody PROTAC conjugates 
    3. Antibody-targeted cytokine therapies
    4. Antibody PK modifiers  

     

Selected Publications

    1. Bordeau BM, TD Nguyen, JR Polli, P Chen, JP Balthasar. Payload-binding Fab fragments increase the therapeutic index of MMAE antibody–drug conjugates. Mol Cancer Ther 2023, 22 (4): 459–470. 
    2. Bordeau BM, Yang Y, Balthasar JP. Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy. Cancer Res 2021, 81, 4145-4154 
    3. Bordeau BM, Abuquyyas L, Nguyen TD, Chen P, Balthasar JP. Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier. Front Pharmacol 2022, 13-2022, 
    4. Bordeau BM, Balthasar JP. Strategies to enhance monoclonal antibody uptake and distribution in solid tumors. Cancer Biol Med. 18(3):649–664 (2021).